Cardiovascular magnetic resonance-guided right heart catheterization in a conventional CMR environment – predictors of procedure success and duration in pulmonary artery hypertension

Table 1 Patient demographics

Characteristic	Finding	Range (min-max)
Age (years)	57 +/− 15	20–83
Female gender, n (%)	40 (80)
Height (m)	1.63 (1.56–1.73)	1.46–1.95
Weight (kg)	71 +/− 16	40–105
BSA (m²)	1.8 +/− 0.2	1.4–2.4
6MWD (metres)	333 (150–440)	0–582
NT-proBNP (ng/L)	320 (110–841)	50–52,746
WHO FC, n (%)
1	2 (4)
2	12 (24)
3	32 (64)
4	4 (8)
PAH, n (%)	39 (78)
Group 1	33 (66)
- Idiopathic	8
- CTD	23
- PVOD	1
- Portopulmonary	1
Group 2	2 (4)
Group 3	2 (4)
Group 4	1 (2)
Group 5	1 (2)
PAH therapy, n (%)
- Phosphodiesterase type 5 inhibitor	24 (48)
- Endothelin receptor antagonist	23 (46)
- Intravenous Epoprostenol	2 (4)

All normally distributed data are presented as mean ± standard deviation, non-parametric data are presented as median (Q1-Q3) and proportions as n (%)
BSA Body surface area, CTD Connective tissue disease, NT-proBNP N-terminal pro-brain natriuretic peptide, PAH Pulmonary artery hypertension, PVOD Pulmonary veno-occlusive disease, WHO FC World Health Organisation Functional Class, 6MWD 6-min walk distance

ISSN: 1532-429X